Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea
Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
Clin Mol Hepatol. 2015;21(4):358-364. Published online 2015 Dec 24 DOI: https://doi.org/10.3350/cmh.2015.21.4.358
Citations to this article as recorded by 
Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease
Mahmoud Saif-Al-Islam, Usama M. Abdelaal, Mustafa Adel Younis, Hisham A. Alghany Algahlan, Safaa Khalaf, Raquel Mart n Venegas
Gastroenterology Research and Practice.2021; 2021: 1. CrossRef
Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials
Jeong Heo, Yoon Jun Kim, Jin-Woo Lee, Ji Hoon Kim, Young-Suk Lim, Kwang-Hyub Han, Sook-Hyang Jeong, Mong Cho, Ki Tae Yoon, Si Hyun Bae, Eric D. Crown, Linda M. Fredrick, Negar Niki Alami, Armen Asatryan, Do Hyun Kim, Seung Woon Paik, Youn-Jae Lee
Gut and Liver.2021; 15(6): 895. CrossRef
Sofosbuvir and Ribavirin with or Without Pegylated-Interferon in Hepatitis C Virus Genotype-2 or -3 Infections: A Systematic Review and Meta-Analysis
Mohammad Ehsan Bayatpoor, Mohammad Hossein Khosravi, Heidar Sharafi, Mohammad Saeid Rezaee-Zavareh, Bita Behnava, Seyed Moayed Alavian
Archives of Clinical Infectious Diseases.2019;[Epub] CrossRef
Sofosbuvir plus ribavirin for the treatment of hepatitis C virus genotype 2 in Korea: What's the optimal dosage of ribavirin in real‐world setting?
Jae Hyun Yoon, Chung Hwan Jun, Ji Ho Seo, Hyun A Cho, Sung Bum Cho, Sung Kyu Choi, Ju Yeon Cho, Man Woo Kim, Sung Wook Lim
Journal of Digestive Diseases.2019; 20(1): 31. CrossRef
Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with β-Thalassemia Major
Rajiv Mehta, Mayank Kabrawala, Subhash Nandwani, Pankaj Desai, Vishwa Bhayani, Sanjay Patel, Viral Parekh
Journal of Clinical and Experimental Hepatology.2018; 8(1): 3. CrossRef
Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C
Song Yang, Huichun Xing, Shenghu Feng, Wei Ju, Shunai Liu, Xiaomei Wang, Weini Ou, Jun Cheng, Calvin Q. Pan
Archives of Virology.2018; 163(2): 467. CrossRef
Early development of de novo hepatocellular carcinoma after direct‐acting agent therapy: Comparison with pegylated interferon‐based therapy in chronic hepatitis C patients
S. H. Yoo, J. H. Kwon, S. W. Nam, H. Y. Kim, C. W. Kim, C. R. You, S. W. Choi, S. H. Cho, J.‐Y. Han, D. S. Song, U. I. Chang, J. M. Yang, H. L. Lee, S. W. Lee, N. I. Han, S.‐H. Kim, M. J. Song, S. Hwang, P. S. Sung, J. W. Jang, S. H. Bae, J. Y. Choi, S. K
Journal of Viral Hepatitis.2018; 25(10): 1189. CrossRef
Ginsenoside Rg3 restores hepatitis C virus–induced aberrant mitochondrial dynamics and inhibits virus propagation
Seong‐Jun Kim, Jae Young Jang, Eun‐Jung Kim, Eun Kyung Cho, Dae‐Gyun Ahn, Chonsaeng Kim, Han Seul Park, Soung Won Jeong, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, Boo Sung Kim, Jihyung Lee, Aleem Siddiqui
Hepatology.2017; 66(3): 758. CrossRef
Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in “real-life” cohort
Rajiv Mehta, Mayank Kabrawala, Subhash Nandwani, Rini Tekriwal, Payal Nandaniya, Mrunal Shah, Vishwa Bhayani
Indian Journal of Gastroenterology.2016; 35(6): 459. CrossRef
Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection
Nina Weiler, Stefan Zeuzem, Martin-Walter Welker
World Journal of Gastroenterology.2016; 22(41): 9044. CrossRef
Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2
Kayo Sugimoto, Soo Ki Kim, Soo Ryang Kim, Mana Kobayashi, Airi Kato, Eri Morimoto, Susumu Imoto, Chi Wan Kim, Yasuhito Tanaka, Masatoshi Kudo, Yoshihiko Yano, Yoshitake Hayashi
Digestive Diseases.2016; 34(6): 627. CrossRef